Background Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was
approved on the basis of a significant improvement in disease-free survival in the KEYNOTE …

Background Immune checkpoint inhibitors are the standard of care for first-line treatment of
patients with metastatic renal cell carcinoma, yet optimised treatment of patients whose …

Background The current available evidence on the management of metastatic renal cell
cancer (mRCC) in real life is scarce in our environment. We present a summary of the …

The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the
approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine …

The immune system consists of specialized cells to perform specific activities to protect the
body against various insults including cancer and infections (1). Immune cells often …

Metastatic neoplasms to the sinonasal tract are rare. Here, we report the case of a 74-year-
old woman with no notable oncological history, presenting to the emergency department …

Simple Summary Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used to
treat a variety of cancers by helping a patient's own immune system to kill cancer cells. ICIs …

Objectives The treatment landscape for metastatic renal cell carcinoma changed a lot in the
last few years. This study aimed to assess the treatment sequences and outcomes for …

Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may
reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which …

Background Long-term follow-up data regarding treatment outcomes of nivolumab plus
ipilimumab combination therapy for advanced renal cell carcinoma as a first-line therapy are …